Insect Larvae as Disposable Bioreactors for Recombinant Protein Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant proteins are hindered by high costs and inefficiencies in large-scale production, particularly in bioreactor-based systems, and existing host systems have limitations in producing complex proteins that require folding and post-translational modifications.
Innovation Solution
The use of insect larvae or pupae, such as Hermetia illucens, for recombinant protein production through genetic transformation, which allows for cost-effective and high-yield production by integrating exogenous genes into the insect genome using transposon-mediated integration and heat shock promoters, enabling scalable and automated protein expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If bioreactor-based systems are used for large-scale recombinant protein production, then production capacity is increased, but production cost increases linearly and efficiency decreases
Solution Approach 1:
The patent employs disposable insect larvae as temporary bioreactors for protein production. The larvae are transformed with the gene of interest, allowed to grow and express the protein, then harvested and discarded after a single use. This disposable approach eliminates the need for expensive, complex bioreactor infrastructure and reduces production costs significantly while maintaining high productivity at scale.
2Ease of manufacture
If prokaryotic culture systems are used to produce recombinant proteins, then production cost is reduced, but ability to produce complex proteins requiring folding and post-translational modifications is lost
Solution Approach 1:
The patent uses insect larvae as a universal production platform that can produce both simple and complex recombinant proteins. The insect expression system provides eukaryotic cellular machinery for proper protein folding and post-translational modifications while maintaining cost-effectiveness. This multi-functional system replaces the need for separate prokaryotic and eukaryotic production systems.
3Ease of manufacture
If yeast systems are used for recombinant protein production, then downstream purification is simplified, but suitability for producing mammalian and proteases-sensitive proteins is reduced
Solution Approach 1:
The patent employs insect larvae as a versatile expression system that maintains eukaryotic protein folding and modification capabilities necessary for producing mammalian and proteases-sensitive proteins. The system provides appropriate cellular environments for these sensitive proteins while still allowing for relatively simple downstream processing through whole-larvae extraction methods.
4Adaptability or versatility
If animal cell systems such as CHO cells are used for mammalian therapeutic protein production, then protein quality and post-translational modifications are improved, but media cost increases significantly
Solution Approach 1:
The patent replaces expensive, nutrient-rich animal cell culture media with simple, inexpensive feed formulations for insect larvae. The larvae consume readily available organic materials and convert them into high-value recombinant proteins. This disposable larval system eliminates the need for costly CHO cell media while maintaining eukaryotic protein quality and post-translational modifications.
Data Source
AI summary
The present disclosure relates to the field of commercial scale production and processing of pharmaceutical liquid or solid compositions derived from insects, wherein the compositions include a purified recombinant protein, vaccine, antibody, peptide, or chemical. Systems and methods to produce the insects and a purified insect-derived recombinant protein, vaccine, antibody, peptide, insecticide, fungicide, or chemical within a bioreactor are also described.